Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2009

01-06-2009 | Case Report

Syndrome of inappropriate antidiuretic hormone secretion associated with acute myeloid leukemia with multilineage dysplasia

Authors: Shoko Nakayama, Taiji Yokote, Kichinosuke Kobayashi, Yuji Hirata, Toshikazu Akioka, Takuji Miyoshi, Takayuki Takubo, Motomu Tsuji, Toshiaki Hanafusa

Published in: Endocrine | Issue 3/2009

Login to get access

Abstract

A patient having acute myeloid leukemia (AML) with multilineage dysplasia, developed hyponatremia and showed all symptoms of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) through a mechanism similar to tumor lysis. Retrospective immunohistochemical analysis of blast cells was positive for antidiuretic hormone (ADH) protein. According to us, this is the first case report of SIADH in an AML patient with multilineage dysplasia, showing blast cells immunostained for ADH, which clearly demonstrated that the tumor cells produced ADH.
Literature
1.
J.B. Sorensen, M.K. Andersen, H.H. Hansen, Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J. Intern. Med. 238, 97–110 (1995)CrossRefPubMed
2.
B.O. Saseed, D. Beaumont, G.H. Handley, J.U. Weaver, Severe hyponatremia: investigation and management in a district general hospital. J. Clin. Pathol. 55, 893–896 (2002)CrossRef
3.
E.S. Jaffe, N.L. Harris, H. Stein (eds.), World Health Organization Classification of Tumors. Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues (IARC Press, Washington, DC, 2006), pp. 88–89
4.
G.L. Robertson, E.A. Mahr, S. Athar et al., Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J. Clin. Invest. 52, 2340–2353 (1973)CrossRefPubMed
5.
K. Kamoi, T. Ebe, A. Hasegawa et al., Hyponatremia in small-cell lung cancer. Mechanisms not involving inappropriate ADH secretion. Cancer 60, 1089–1093 (1987)CrossRefPubMed
6.
A.F. List, J.D. Hainsworth, B.W. Davis et al., The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J. Clin. Oncol. 4, 1191–1198 (1986)PubMed
7.
R.T. Eagen, L.H. Maurer, R.J. Forcier, M. Tulloh, Small cell carcinoma of the lung: Staging, paraneoplastic syndromes, treatment, and survival. Cancer 33, 527–532 (1974)CrossRef
8.
J.A. Lockton, N. Thatcher, A retrospective study of 32 patients with small-cell bronchogenic carcinoma and inappropriate secretion of antidiuretic hormone. Clin. Radiat. 37, 527–532 (1986)
9.
R. Watabe, K. Shibata, N. Hirase et al., Angioblastic B-cell lymphoma with hemophagocytic syndrome associated with syndrome of inappropriate secretion of antidiuretic hormone. Ann. Hematol. 79, 581–584 (2000)CrossRefPubMed
10.
M. Ciaudo, L. Chauvenet, J. Audouin et al., Peripheral T-cell lymphoma with hemophagocytic histiocytosis localizedto the bone marrow associated with inappropriate secretion of antidiuretic hormone. Leuk. Lymphoma 19, 511–514 (1995)CrossRefPubMed
11.
F. Demirkan, F. Vural, G.H. Ozsan et al., Hemophagocytic syndrome associated with inappropriate secretion of antidiuretic hormone in lymphoma and acute myeloblastic leukemia: report of two cases. Leuk. Lymphoma 42, 1401–1404 (2001)CrossRefPubMed
12.
P.K. Bondy, E.D. Gilby, Endocrine function in small cell undifferentiated carcinoma of the lung. Cancer 50, 2147–2153 (1982)CrossRefPubMed
13.
14.
S.B. Kaye, E.J. Ross, Inappropriate antidiuretic hormone (ADH) secretion in association with carcinoma of the bladder. Postgrad. Med. J. 53, 274–277 (1977)CrossRefPubMed
15.
D.F. Hayes, R.M. Lechan, M.R. Posner et al., The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck. J. Surg. Oncol. 32, 150–152 (1986)CrossRefPubMed
Metadata
Title
Syndrome of inappropriate antidiuretic hormone secretion associated with acute myeloid leukemia with multilineage dysplasia
Authors
Shoko Nakayama
Taiji Yokote
Kichinosuke Kobayashi
Yuji Hirata
Toshikazu Akioka
Takuji Miyoshi
Takayuki Takubo
Motomu Tsuji
Toshiaki Hanafusa
Publication date
01-06-2009
Publisher
Springer US
Published in
Endocrine / Issue 3/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9171-5

Other articles of this Issue 3/2009

Endocrine 3/2009 Go to the issue

Original Paper

Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-κB activation

Invited Review

Calcium-sensing receptor in cancer: good cop or bad cop?

Original Paper

Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density

Original Paper

Serum albumin protects from cytokine-induced pancreatic β cell death by a phosphoinositide 3-kinase-dependent mechanism

Original Paper

Mutations and polymorphisms in the SDHB, SDHD, VHL, and RET genes in sporadic and familial pheochromocytomas

Original Paper

Carotid stiffness and microalbuminuria in patients with type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits